Individuals who are hepatitis B virus carriers cannot receive the hepatitis B vaccine. This is because their serological test results show positive for hepatitis B surface antigen, indicating that the hepatitis B virus is already present in their bodies. With proper and effective treatment, it is possible for these individuals to develop hepatitis B surface antibodies. Once these antibodies are produced, they provide immunity against the hepatitis B virus, effectively protecting the person from infection. In this case, the vaccination becomes unnecessary, as the body has already achieved the same protective effect. Additionally, if a hepatitis B virus carrier were to receive the hepatitis B vaccine, it could potentially trigger an immune response to the virus, which might lead to liver damage.